Lodo Therapeutics Corp.
http://www.lodotherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lodo Therapeutics Corp.
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
Genentech Mines The Microbiome Again With IBD Deal
Genentech is to work with microbiome therapeutics company Microbiotica in a collaboration to discover, develop and commercialise treatments for inflammatory bowel disease.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Conifer Point Pharmaceuticals, LLC
- Hibiskus Biopharma, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice